NSN "Neurosona Presents Interim Clinical Results of Depression Treatment at World Focused Ultrasound Foundation Symposium"

[Asia Economy Reporter Hyunseok Yoo] A mid-term analysis result from a clinical trial of a brain disease treatment device developed by NSN's subsidiary Neurosona showed a significant improvement in symptoms of depression patients.

On the 30th, NSN announced that Professor Seok Jeong-ho of the Department of Psychiatry at Yonsei University Gangnam Severance Hospital, who is conducting a clinical trial using Low-Intensity Focused Ultrasound (LIFU) jointly with Neurosona, presented the mid-term analysis results of the clinical trial titled "Effect of Low-Intensity Focused Ultrasound Stimulation on Major Depressive Disorder Patients" at the 7th International Focused Ultrasound Symposium held online by the Focused Ultrasound Foundation.

According to Professor Seok Jeong-ho, "In this clinical trial conducted in collaboration with Professor Seung-sik Yoo of Harvard Medical School, we stimulated the brain region known to have impaired function in depression patients (left dorsolateral prefrontal cortex) using Low-Intensity Focused Ultrasound (LIFU)," and added, "We measured depression symptoms at three time points: before ultrasound stimulation, immediately after ultrasound stimulation, and two weeks after ultrasound stimulation, comparing the group that received actual ultrasound stimulation with the group that received sham stimulation."

He continued, "Through this clinical study, we derived mid-term results showing that using Low-Intensity Focused Ultrasound (LIFU) leads to a significant improvement in depression symptoms in the group that received actual stimulation compared to the group that received sham stimulation."

Neurosona, a specialized brain disease treatment device company, is conducting exploratory clinical trials on depression patients visiting Yonsei University Gangnam Severance Hospital together with Professor Seok Jeong-ho, who has extensive clinical experience and research background in brain stimulation therapy for depression brain function regulation, using its self-developed brain disease treatment device ‘Neurosona (NEUROSONA)’.

‘Neurosona (NEUROSONA)’ is a medical device that is highly anticipated for treating various brain diseases such as depression, Alzheimer's, pain, consciousness disorders, sleep disorders, and stroke. NSN and its subsidiary Neurosona are conducting clinical research on these brain disease treatments in collaboration with leading hospitals in Korea.

A Neurosona official stated, "The clinical trial led by Professor Seok Jeong-ho is the world's first clinical trial conducted by dividing depression patients into a treatment group receiving actual stimulation and a group receiving sham stimulation to investigate the efficacy and safety of Low-Intensity Focused Ultrasound (LIFU) for depression treatment," and emphasized, "Since Low-Intensity Focused Ultrasound (LIFU) has been found to have significant efficacy in treating depression, it is expected that after approval clinical trials and sales approval by the Ministry of Food and Drug Safety, the official product launch of ‘Neurosona (NEUROSONA)’ will be possible."